ProSomnus Sleep Technologies, featuring the award-winning MicrO2® Obstructive Sleep Apnea and Snore Device, announced that it has separated from MicroDental Laboratories. This strategic move enables ProSomnus to operate as a standalone business and concentrate resources on partnering with dentists to treat the rapidly growing number of patients with obstructive sleep apnea (OSA).
OSA is a sleep breathing disorder affecting an estimated 20 million adults in the United States. OSA has been linked with an increased risk of stroke, cardiovascular problems, motor vehicle accidents, depression, memory loss, and snoring. The economic impact of OSA is estimated to be between $65 billion and $165 billion per year.
“ProSomnus invents and manufactures devices that enable dentists to treat more patients who are suffering from OSA. Tens of millions of adults have undiagnosed OSA, millions of adults have abandoned CPAP, and dentists can help,” says Len Liptak, CEO of ProSomnus Sleep Technologies. “Separating from MicroDental Laboratories enables ProSomnus to accelerate development of the key products, processes, and programs that are integral to this plan.”
ProSomnus Sleep Technologies is a member of HealthpointCapital’s portfolio of investments. HealthpointCapital is a value-driven, research-oriented private equity firm that has invested in innovative dental and orthopedic medical device companies.
“A few years ago, HealthpointCapital identified the obstructive sleep apnea market as an attractive opportunity,” says Laing Rikkers, Managing Director at HealthpointCapital. “HealthpointCapital invests in innovative device companies that are addressing underserved healthcare issues, and ProSomnus fits this profile. We look forward to partnering with the leadership team at ProSomnus to expand the oral appliance therapy segment of the sleep apnea market.”